Business
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on
About this update from Larimar Therapeutics, Inc.
[{"type":"text","content":"BALA CYNWYD, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced upcoming presentations at the United Mitochondrial Disease Foundation Mitochondrial Medicine 2022 meeting and XXIV World Congress International Society for Heart Research. Details on the presentations are shown below. United Mitochondrial Disease Foundation Mitochondrial Medicine 2022 Conference Location:AAA 4-Diamond JW Marriott Phoenix Desert Ridge Resort & Spa (Phoenix, Arizona)Presentation Title:Frataxin (FXN) Promotes the Expression of Neuronal Differentiation Markers: Effect of FXN Supplementation in a Neurodegeneration ModelPresentation Format:OralPresenting Author:Matthew Baile, Ph.D., Senior Research Investigator, Larimar TherapeuticsPresentation Date:June 9, 2022Presentation Time:5:30 PM PDT During the presentation, Dr. Baile will discuss preclinical studies performed in in vitro and in vivo disease models that evaluated CTI-1601’s effects on gene expression and neurodegeneration. XXIV World Congress International Society for Heart Research Conference Location:Mercure Hotel MOA Berlin (Berlin, Germany)Presentation Title:Lipidomics Insights into Mitochondrial Disorders & Heart FailurePresentation Format:OralPresenting Author:Christine Des Rosiers, Ph.D., Director, Metabolomic Laboratory & Platform, Montreal Heart Institute; Honorary and Associate Professor, Department of Nutrition, Université de MontréalPresentation Date:June 15, 2022Presentation Time:To take place during the congress’s “Multi-omics Approaches to Understand Heart Failure” symposium, which is scheduled for 9:45 AM – 11:45 AM CEST During the presentation, Dr. Des Rosiers will present the results of collaborative studies with Larimar that analyzed the lipidomic profiles of samples from healthy individuals and from patients with Friedreich's ataxia that were untreated or treated with CTI-1601 during Larimar’s Phase 1 multiple-ascending dose clinical trial. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also ...